Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DoJ Bull’s Eye: Off-Label Promotion, Formulary Placements, FCPA Violations Remain Targets

Executive Summary

A Pfizer attorney says government saber rattling over individual liability does not mean there will be a spike in individual prosecutions; Pfizer’s cooperation with the government helped it avoid criminal resolution in a Foreign Corrupt Practices Act settlement.

You may also be interested in...



Pfizer Settles Foreign Bribery Charges With Prosecution Deferred

Pfizer settles with DoJ and SEC to resolve charges its subsidiaries bribed foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ. In a separate case, Pfizer’s Wyeth subsidiary agrees to pay $18.9 million in disgorgement of net profits and prejudgment interest to SEC.

Pfizer Settles Foreign Bribery Charges With Prosecution Deferred

Pfizer settles with DoJ and SEC to resolve charges its subsidiaries bribed foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ. In a separate case, Pfizer’s Wyeth subsidiary agrees to pay $18.9 million in disgorgement of net profits and prejudgment interest to SEC.

Pfizer Settles Foreign Bribery Charges, Wins Deferred Prosecution For Helping Government

Pfizer reaches separate settlements with U.S. DoJ and SEC to resolve charges its subsidiaries bribed Chinese, Russian and other foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel